Abstract
This review article assesses the currently available data on new drugs used on and off license for overactive bladder, highlighting the range of pharmacological options. The drugs being considered are solifenacin, darifenacin, transdermal oxybutynin, modified-release propiverine, intravesical botulinum toxin, duloxetine and desmopressin. Although these agents encompass several different modes of action, there is still little evidence to help decide which agent might suit which patient. Furthermore, there have been limited head-to-head studies comparing the efficacy and tolerability of newer drugs. The article concludes with a speculative 5-year view of future developments in the pharmacology of overactive bladder.
Financial & competing interests disclosure
Professor Cardozo undertakes research, advisory work and/or consultancies in association with the following companies: Astellas, Pfizer, UCB Pharma, Organon, BioXell and Icon. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.